Related Experiment Video
Updated: Jul 16, 2025
06:29
Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
2.4K
Quantitative Ocular Surface Changes in Patients Undergoing Immune Checkpoint Inhibitor Therapy
Kevin Chen1, Maria Carolina Ibañez Bruron2, Sebastian Mondaca3
1Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Ocular Immunology and Inflammation
|September 18, 2023
Summary
Immune checkpoint inhibitor (ICI) therapy can cause ocular surface changes, including dryness. Treatments like artificial tears and corticosteroids can help stabilize these conditions in patients undergoing ICI treatment.
Area of Science:
- Ophthalmology
- Oncology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are increasingly used in cancer therapy.
- Ocular surface complications are a potential side effect of ICI treatment.
- Understanding these effects is crucial for patient management.
Purpose of the Study:
- To describe the clinical course of ocular surface changes in patients receiving ICI therapy.
- To evaluate the effectiveness of various treatments for these ocular surface conditions.
Main Methods:
- Evaluation of multiple ocular surface dryness markers in 16 patients on ICI therapy.
- Statistical analysis using the Wilcoxon rank-sum test to assess changes in ocular surface indices.
- Assessment of treatment interventions including artificial tears, cyclosporine, corticosteroids, warm compresses, and punctal plugs.
Main Results:
- 50% of eyes showed worsening Schirmer I scores, and 29% had increased lissamine green staining.
- 43% of patients experienced a decline in Ocular Surface Disease Index (OSDI) scores.
- Common treatments included artificial tears (88%), cyclosporine (25%), and topical corticosteroids (31%).
Conclusions:
- A significant number of patients on ICI therapy develop ocular surface changes.
- Medical interventions can effectively stabilize ocular surface disease in this patient population.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
477
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
477
01:28Angle Closure Glaucoma: Treatment
559
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
559